Jim Cramer’s Bold Prediction on Regeneron Pharmaceuticals

In a striking admission, Jim Cramer has recently expressed that he overlooked a gem in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). While addressing a caller’s inquiry about the stock, he remarked:

“I should have been recommending Regeneron. That Len Schleifer pulled the rabbit out of a hat. It’s coming right back right now. By the way, I’ll give you a twofer, so is Amgen.”

A Closer Look at Regeneron

Regeneron has positioned itself as a significant player in the pharmaceutical landscape, providing treatments for a range of conditions including eye disorders, immune system issues, cancer, cardiovascular diseases, infections, and even rare illnesses. Cramer highlighted its remarkable performance, recalling that just last year, he was discussing the stock as one of the standout performers over the last two decades. He stated:

“Rearrange Repligen’s ticker just a bit and you’ll get the ninth best stock of the Mad Money era, Regeneron Pharma, that’s up more than 9,400%. Now this one’s special to me because Regeneron’s co-founder and CEO, Dr. Len Schleifer, he was one of the first guests who ever came on the show back in April 12th, 2005. The stock was trading at less than five bucks a share. Now it’s at $568, and that’s after a 6.87% surge today.”

Comparative Insights and Future Prospects

While Cramer acknowledges the merit of investing in REGN, comparisons arise with certain AI stocks presenting even greater potential. These AI stocks, positioned to thrive amidst current economic trends like Trump-era tariffs and the onshoring movement, might offer lower risks and higher upside advantages. For those curious about lucrative investment opportunities in undervalued AI stocks, an intriguing report is available that identifies a promising contender with a massive upside potential.

In this ever-evolving market landscape, where precision and informed decisions are crucial, Cramer’s pronounced advocacy for Regeneron emphasizes both the stock’s historic performance and the captivating narrative of its rise, indicative of both opportunity and substantial investor interest.

Conclusion

Cramer’s insights on Regeneron not only shed light on a potent investment opportunity but also set the stage for discussions around emerging sectors such as AI. The pharmaceutical landscape remains vibrant, especially with key players like Regeneron making headlines and proving their worth in a competitive market.

Source: finance.yahoo.com/news/jim-cramer-says-recommending-regeneron-195118224.html